




## Genoscience Pharma has announced a new agreement for research at the Hebrew University of Jerusalem on targeted degradation technology

**MARSEILLE-JERUSALEM, April 19, 2023** – Genoscience Pharma a clinical-stage biopharmaceutical company that develops disruptive therapeutics for the treatment of cancer patients, announced today a new research agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., the wholly owned subsidiary and technology transfer company of the Hebrew University of Jerusalem.

The collaboration aims to expand the development of PROTAC technology on investigative Genoscience agents, which can increase the potency and selectivity of small molecule drugs and overcome cancer resistance to existing therapies. Overall, PROTAC technology has the potential to enhance the activity of small molecule drugs and broaden the range of proteins that can be targeted for therapeutic purposes, providing a new avenue for drug development.

The research will be led by Professor Raphael Benhamou, Ph.D., at the Faculty of Medicine of the Hebrew University of Jerusalem. Prof. Benhamou is an internationally recognized researcher who develops tools for targeted degradation therapy of RNA complexes associated with diseases. The development of targeted degradation therapies has transformed the treatment and improved clinical responses of patients with many types of tumors. However, effective targeted therapies for difficult-to-treat cancers are still lacking, and new therapeutic strategies are needed to prevent relapse and metastasis in these diseases.



(Photo credit: [Nature Reviews Drug Discovery](#) 21, 181–200 (2022))

### About ezurpimtrostat (GNS561)

Ezurpimtrostat is a first-in-class, orally bioavailable, small molecule that blocks cancer cell proliferation by inhibiting late-stage autophagy and dose-dependent build-up of enlarged lysosomes by interacting with the palmitoyl-protein thioesterase 1 (PPT1). Preclinical and clinical studies have found evidence of its high degree of tropism in the liver and powerful anti-tumor activity.

### About Genoscience Pharma

Genoscience Pharma is a French biotech company developing unique small molecules in Oncology. This is the first clinical stage company ever with unique lysosomotropic agents assessed in a global



clinical trial. Its mission is to conceptualize and develop disruptive and innovative science from bench to bedside for improving the conditions of patients in serious unmet medical needs.

[www.genosciencepharma.com](http://www.genosciencepharma.com)

### **About Yissum**

Yissum is the technology transfer company of The Hebrew University of Jerusalem. Founded in 1964, it serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors, and industry. Yissum's mission is to benefit society by converting extraordinary innovations and transformational technologies into commercial solutions that address our most urgent global challenges. Yissum has registered over 11,500 patents globally; licensed over 1,140 technologies and has spun out more than 245 companies. Yissum's business partners span the globe and include companies such as Boston Scientific, ICL, Intel, Johnson & Johnson, Merck, Novartis, and many more. For further information please visit [www.yissum.co.il](http://www.yissum.co.il)

### **Forward-looking statements**

This press release may involve and contain forward-looking statements by the company about its product candidate GNS561, including its potential benefits. Such statements are based upon the current beliefs and expectations of Genoscience Pharma's management and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, but are not limited to: additional financing, the company's ability to implement its chosen strategy, dependence upon third parties, other risks and uncertainties inherent in research and development, including the possibility of unfavorable study results, changes in the competitive environment, changes in regulations, clinical or industrial risks and all risks linked to the company's growth. There are no guarantees that future clinical trials will be completed or successful or that any Genoscience Pharma therapeutics will receive regulatory approval for any indication or prove to be commercially successful. While those factors presented here are considered representative, no such list should be considered a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof; Genoscience Pharma does not undertake any obligation to update such statements to reflect subsequent events or circumstances.

---

### **Genoscience contact**

Agnes Menut

[a.menut@genosciencepharma.com](mailto:a.menut@genosciencepharma.com)

FR: +33 (0)6 16 50 00 77